Lyrica ® — Net Sales
Viatris Lyrica ® — Net Sales increased by 0.7% to $120.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.1%, from $112.60M to $120.60M. Over 4 years (FY 2021 to FY 2025), Lyrica ® — Net Sales shows a downward trend with a -9.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase suggests successful brand retention or pricing power, while a decrease typically signals market share erosion due to generic entry or product maturity.
Detailed definition
This metric represents the total revenue generated from the sale of the Lyrica brand product line after accounting for r...
Peer comparison
Similar to legacy brand revenue metrics in other pharmaceutical companies, where performance is often benchmarked against the rate of decline following loss of exclusivity.
vtrs_segment_lyrica_net_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $192.50M | $175.60M | $172.60M | $171.70M | $155.80M | $156.50M | $139.90M | $144.30M | $137.10M | $141.70M | $133.40M | $114.20M | $124.30M | $129.90M | $127.00M | $112.60M | $128.10M | $126.50M | $119.80M | $120.60M |
| QoQ Change | — | -8.8% | -1.7% | -0.5% | -9.3% | +0.4% | -10.6% | +3.1% | -5.0% | +3.4% | -5.9% | -14.4% | +8.8% | +4.5% | -2.2% | -11.3% | +13.8% | -1.2% | -5.3% | +0.7% |
| YoY Change | — | — | — | — | -19.1% | -10.9% | -18.9% | -16.0% | -12.0% | -9.5% | -4.6% | -20.9% | -9.3% | -8.3% | -4.8% | -1.4% | +3.1% | -2.6% | -5.7% | +7.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Viatris's lyrica ® — net sales?
- Viatris (VTRS) reported lyrica ® — net sales of $120.60M in Q1 2026.
- How has Viatris's lyrica ® — net sales changed year-over-year?
- Viatris's lyrica ® — net sales increased by 7.1% year-over-year, from $112.60M to $120.60M.
- What is the long-term trend for Viatris's lyrica ® — net sales?
- Over 4 years (2021 to 2025), Viatris's lyrica ® — net sales has grown at a -9.6% compound annual growth rate (CAGR), from $728.50M to $487.00M.
- What does lyrica ® — net sales mean?
- The total revenue earned from sales of the Lyrica pharmaceutical product.